uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 10,438 Shares of Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 10,438 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares in the company, valued at $2,240,441.70. The trade was a 4.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Christian Klemt also recently made the following trade(s):

• On Thursday, February 27th, Christian Klemt sold 2,916 shares of uniQure stock. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12.
• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The stock was sold at an average price of $7.55, for a total transaction of $13,559.80.

uniQure Trading Up 6.7 %

Shares of NASDAQ:QURE opened at $12.09 on Thursday. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company’s 50 day moving average is $14.69 and its two-hundred day moving average is $9.91. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $589.30 million, a PE ratio of -2.44 and a beta of 0.38.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. Cantor Fitzgerald upped their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. The Goldman Sachs Group upped their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Wells Fargo & Company decreased their price objective on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a report on Friday, February 28th. Finally, StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

Institutional Investors Weigh In On uniQure

Large investors have recently modified their holdings of the company. Twin Tree Management LP purchased a new stake in shares of uniQure in the 4th quarter valued at approximately $77,000. FNY Investment Advisers LLC purchased a new stake in shares of uniQure in the 4th quarter valued at approximately $88,000. RTW Investments LP purchased a new stake in shares of uniQure in the 3rd quarter valued at approximately $49,000. ADAR1 Capital Management LLC purchased a new position in shares of uniQure in the 4th quarter valued at $177,000. Finally, Atria Investments Inc purchased a new position in shares of uniQure in the 3rd quarter valued at $53,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.